Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.66 is 41% above its 5-year average of -1.11, around the middle of its 5-year range (-2.58–0.66).
676.47% below its 12-month average of -0.08.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.07.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 19 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:56:00.246Z. Historical observations retain their original dates. Historical series through 2025-05-05.
EARNINGS PER SHARE (EPS)
-0.66
EARNINGS PER SHARE (EPS) AVG TTM
-0.08
EARNINGS PER SHARE (EPS) AVG 3Y
-1.22
EARNINGS PER SHARE (EPS) AVG 5Y
-1.11
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-676.47%
CURRENT VS 3Y AVG
+46.01%
CURRENT VS 5Y AVG
+40.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Castle Biosciences, Inc.
Market Cap
$1.04B
Earnings Per Share (EPS)
-0.66
TTM Avg
-0.08
3Y Avg
-1.22
5Y Avg
-1.11
Market Cap
$1.04B
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.56
3Y Avg
-1.49
5Y Avg
-1.15
Market Cap
$1.04B
Earnings Per Share (EPS)
-1.84
TTM Avg
-0.83
3Y Avg
-0.99
5Y Avg
-2.01
Market Cap
$1.03B
Earnings Per Share (EPS)
-0.09
TTM Avg
-3.41
3Y Avg
-0.94
5Y Avg
-0.03
Market Cap
$1.05B
Earnings Per Share (EPS)
-0.99
TTM Avg
-3.50
3Y Avg
-23.24
5Y Avg
-16.84
Market Cap
$1.06B
Earnings Per Share (EPS)
-3.37
TTM Avg
-3.42
3Y Avg
-2.02
5Y Avg
-1.79
Market Cap
$1.02B
Earnings Per Share (EPS)
-0.38
TTM Avg
-0.83
3Y Avg
-0.98
5Y Avg
-0.98
Market Cap
$1.01B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
Earnings Per Share (EPS)
1.79
TTM Avg
1.65
3Y Avg
1.42
5Y Avg
1.09
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.04B | -0.66 | -0.08 | -1.22 | -1.11 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | -1.64 | -1.56 | -1.49 | -1.15 |
| Immatics N.V. (IMTX)vs › | $1.04B | -1.84 | -0.83 | -0.99 | -2.01 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.09 | -3.41 | -0.94 | -0.03 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -0.99 | -3.50 | -23.24 | -16.84 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.06B | -3.37 | -3.42 | -2.02 | -1.79 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -0.38 | -0.83 | -0.98 | -0.98 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 1.79 | 1.65 | 1.42 | 1.09 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $998.31M | -2.97 | -9.41 | -6.16 | -6.16 |
Trailing EPS (TTM)
$-0.66
Forward EPS (Est.)
$-1.27
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.83 |
| 2024-12-31 | 0.66 |
| 2023-12-31 | -2.14 |
| 2022-12-31 | -2.58 |
| 2021-12-31 | -1.24 |
| 2020-12-31 | -0.54 |
| 2019-12-31 | 0.35 |
| 2018-12-31 | -0.60 |
| 2017-12-31 | -1.26 |
